We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Ironwood Pharmaceuticals Inc (IRWD) Common Stock A USD0.001

Sell:$10.99 Buy:$11.00 Change: $0.07 (0.64%)
Market closed |  Prices as at close on 21 January 2022 | Switch to live prices |
Sell:$10.99
Buy:$11.00
Change: $0.07 (0.64%)
Market closed |  Prices as at close on 21 January 2022 | Switch to live prices |
Sell:$10.99
Buy:$11.00
Change: $0.07 (0.64%)
Market closed |  Prices as at close on 21 January 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Ironwood Pharmaceuticals, Inc. is a gastrointestinal (GI) healthcare company. The Company is focused on the development and commercialization of GI product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC). It operates in human therapeutics business segment. Its product candidate LINZESS (linaclotide) is available to adult men and women suffering from IBS-C or CIC in the United States, and Mexico and to adult men and women suffering from IBS-C in Japan and China. Its linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC in Canada, and to adult men and women suffering from IBS-C in certain European countries.

Contact details

Address:
100 Summer St Ste 2300
BOSTON
02110-2156
United States
Telephone:
+1 (617) 6217722
Website:
www.ironwoodpharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
IRWD
ISIN:
US46333X1081
Market cap:
$1.83 billion
Shares in issue:
163.65 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Julie Mchugh
    Executive Chairman of the Board
  • Thomas McCourt
    President, Chief Executive Officer, Director
  • Sravan Emany
    Chief Financial Officer, Senior Vice President
  • Jason Rickard
    Chief Operating Officer, Senior Vice President
  • John Minardo
    Senior Vice President, Chief Legal Officer
  • Michael Shetzline
    Chief Medical Officer, Senior Vice President and Head of Drug Development
  • Ronald Silver
    Principal Accounting Officer, Corporate Controller

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.